Showing results (111-120 of 143) with videos related to
Sort By:
Pageof 15
Melanoma Research|November 25, 2020
Safety and efficacy of combination nivolumab plus ipilimumab in patients with advanced melanoma: results from a North American expanded access program (CheckMate 218)F Stephen Hodi, Paul B Chapman, Mario Sznol, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 15, 2022
Targeting MDSC Differentiation Using ATRA: A Phase I/II Clinical Trial Combining Pembrolizumab and All-Trans Retinoic Acid for Metastatic MelanomaRichard P Tobin, Dasha T Cogswell, Victoria M Cates, et al.Journal of the American Academy of Dermatology|March 10, 2015
Gene expression profiling for molecular staging of cutaneous melanoma in patients undergoing sentinel lymph node biopsyPedram Gerami, Robert W Cook, Maria C Russell, et al.Molecular Cancer Research : MCR|October 22, 2020
Studying Immunotherapy Resistance in a Melanoma Autologous Humanized Mouse XenograftJ Jason Morton, Nathaniel Alzofon, Stephen B Keysar, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 19, 2012
Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitorKevin B Kim, Richard Kefford, Anna C Pavlick, et al.Journal for Immunotherapy of Cancer|September 24, 2016
A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanomaElizabeth I Buchbinder, Anasuya Gunturi, Jessica Perritt, et al.European Journal of Cancer (Oxford, England : 1990)|June 27, 2017
Health-related quality of life results from the phase III CheckMate 067 studyDirk Schadendorf, James Larkin, Jedd Wolchok, et al.Cancer Immunology, Immunotherapy : CII|October 8, 2016
Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinomaAjjai Alva, Gregory A Daniels, Michael K K Wong, et al.Molecular Cancer Therapeutics|October 22, 2017
ALK Inhibitor Response in Melanomas Expressing <i>EML4-ALK</i> Fusions and Alternate <i>ALK</i> IsoformsKasey L Couts, Judson Bemis, Jacqueline A Turner, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 20, 2015
Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT InhibitionRichard D Carvajal, Donald P Lawrence, Jeffrey S Weber, et al.Pageof 15